Dilution is on the way, causing at least temporary pain for shareholders.
Another bump in the road for Acthar is weighing on the drugmaker.
Here's what Gilead's getting with its $5.1 billion Galapagos collaboration.
Looking for bargains? You'll definitely want to check out these dirt-cheap healthcare stocks.
You might think it's too late to profit with this soon-to-be-acquired drug stock. Think again.
Being a copycat just might pay off with these three stocks.
Pure-play pot stock or its big partner? Here's which stock looks more attractive over the long run.
Great growth prospects and relatively modest risk levels make these biotech stocks really attractive.
CannTrust messed up big time by violating Health Canada regulations. What should investors do in the wake of the scandal?
Which stock wins in a head-to-head matchup between these two big drugmakers?
Weak preliminary Q2 results are weighing heavily on the genomic sequencing specialist.
These biotech stocks have at least quadrupled in just over six months this year.
These stocks stand at the forefront of a growing multibillion-dollar industry.
You can understand how to invest in health insurer stocks in just seven steps.
A big reversal by the White House improved the financial outlook for the big health insurer.
Investors cheered the surgical robot maker's sale of assets and the added cash the divestiture will bring.
How big does a company's market cap need to be to make the top 10 list of healthcare stocks? $111 billion.
Investors disliked the biotech's bad news a lot more than they liked its good news.
These big companies could be big winners.
Aurora might be late to the battle in the U.S., but the company just might eventually claim the throne in the global hemp CBD market.